OOIR: Observatory of International Research

Papers

(The median citation count of Biodrugs is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond	350
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis	297
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis	127
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy	103
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome	93
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor	92
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making	78
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery	62
Acknowledgement to Referees	61
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials	60
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart	49
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies	44
CAR-T Cells and the Kidney: Insights from the WHO Safety Database	40
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–2022	40
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?	38
Cell Engineering for Increasing Production of Recombinant Proteins in Mammalian Cells	36
Correction: Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer: A Nationwide Cohort Study in France	36
The Present and Future of Monoclonal Antibody Therapies for Multiple Sclerosis	36
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review	35
Malaria Vaccines: Progress to Date	34
Progress and Challenges in the Treatment of Fabry Disease	34
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase	33
Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective Study	32
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?	32
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer	31

Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects	30
Interleukin-23 Inhibitors in Inflammatory Bowel Disease	30
Acknowledgement to Referees	29
Real-World Evidence on the Effectiveness and Safety of Spesolimab in the Treatment of Generalized Pustular Psoriasis Flares: A Case Series	29
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review	28
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options	28
Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?	26
Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment	26
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network	25
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy	25
Recombinant Protein Drugs: A 2025 Update	25
Advanced Combination Therapy in Inflammatory Bowel Disease: What Does the Future Hold?	25
Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study	24
Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa	24
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Stu	23
Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects	21
Tolerability and Reactogenicity Profile of mRNA SARS-Cov-2 Vaccines from a Mass Vaccination Campaign in a Tertiary Hospital: Between-Vaccine and Between-Population Prospective Observational Study (Vig	20
Understanding IgM Structure and Biology to Engineer New Antibody Therapeutics	20
Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight	20
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review	19
Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study	19
The Use of Biologics for Thyroid Eye Disease	19
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis	18
Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials	18
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database	18
Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab	18
Extracellular Vesicles and Immune Activation in Solid Organ Transplantation: The Impact of Immunosuppression	18
Biosimilar Uptake in Spain from 2016 to 2023: Analysis Based on Official Data Collection	17
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine	17
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs	16
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies	16
Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria	15
CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance	14
Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases	14
Advances of Antimicrobial Peptides in the Treatment of Multidrug-Resistant Bacteria	14
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease	13
Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing	13
Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context	13
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers	13
Patients’ Perceptions of Biosimilars: A Systematic Review	13
Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study	12
Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method	12
Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilan	12
Bidirectional Interplay Between IBD Therapies and the Gut Microbiota: A Pharmacomicrobiomic Approach to Personalized Treatment	12
The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases	12
Correction to: Is the Availability of Biosimilar Adalimumab Associated with Budget Saving? A Difference-in-Difference Analysis of 14 Countries	12
Advances in Engineered Virus-Like Particles for Genome Editing and Therapy	11
Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins	11
Site-Specific Genomic Markers Associated with Outcomes of PD-1 Blockade in Gastric and Esophagogastric Junction Cancer: Analysis of Japan’s C-CAT Registry	11
Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure	11

Risankizumab in Patients with Psoriasis with Current or Previous Malignancy: A Multicenter, Retrospective Real-World Study	10
Unlocking the Power of Complement-Dependent Cytotoxicity: Engineering Strategies for the Development of Potent Therapeutic Antibodies for Cancer Treatments	10
Switching from Adalimumab Reference Product to and Among Adalimumab Biosimilars Outside the USA: Insights for US Clinicians	10
Conditionally Activatable Antibody Platforms: Mechanisms, Modalities, and Clinical Translation Potential	10
Correction to: Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study	9
Cardiovascular Adverse Drug Reactions of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: An Analysis from the European Spontaneous Adverse Event Reporting System	9
Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs	9
Antibody-Drug Conjugates in Gynecologic Oncology: Advances, Challenges, and Future Directions	9
Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer	9
Enzyme Engineering Strategies for the Bioenhancement of l-Asparaginase Used as a Biopharmaceutical	9
Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region	9
Correction: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy	9
Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the Association	9
Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline	9
Plant-Derived Human Vaccines: Recent Developments	9
Copies of Biological Medicines: Similar But Not the Same?	8
Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness	8
Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry Disease	8
A Population Pharmacokinetic Model of Tocilizumab in Kidney Transplant Patients Treated for Chronic Active Antibody-Mediated Rejection: Comparison of Plasma Exposure Between Intravenous and Subcutaneo	8
Emerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges	8
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching	8
Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study of GB223, a Fully-Humanized Monoclonal Antibody to RANKL, in Healthy Chinese Adults	8
An Automated Tool for Glycosimilarity Assessment of mAb Therapeutic Biosimilars: Trastuzumab and Bevacizumab as Case Studies	8
Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus	8
The Role of Biologics in the Treatment of Chronic Rhinosinusitis	8
Effect of Biological Therapy for Psoriasis on the Development of Psoriatic Arthritis: A Population-Based Cohort Study	8
Antibody–Drug Conjugates in the Treatment of Urothelial Cancer	8
Progress in Designing Cytokine Antagonist Antibodies for Cancer Therapy	8
First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects	7
Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines	7
Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study	7
Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases	7
Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One	7
The Role of OX40 Pathway Inhibition as a New Therapeutic Strategy for Atopic Dermatitis	7
Sequelae of B-Cell Depleting Therapy: An Immunologist’s Perspective	7
Investigational RNA Interference Agents for Hepatitis B	7
Evaluating Gene Therapy as a Potential Paradigm Shift in Treating Severe Hemophilia	7
Treatment with Biologic Drugs in Pediatric Behçet’s Disease: A Comprehensive Analysis of the Published Data	7
Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review	7
Acknowledgement to Referees	7
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study	7
Lupus Nephritis: New and Emerging Biologic and Targeted Therapies	7
Programmed Cell Death Protein 1-Interleukin-2 Bispecific Agents for Cancer Therapy	7
Staying Ahead of the Game: How SARS-CoV-2 has Accelerated the Application of Machine Learning in Pandemic Management	6
Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies	6
Complement Inhibition in Kidney Transplantation: Where Are We Now?	6
Acknowledgement to Referees	6
Current Developments in the Preclinical and Clinical use of Natural Killer T cells	6
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management	6
Phase I Studies of HLX26, A Novel Anti-LAG-3 Antibody, Monotherapy or Combination Therapy in Patients with Advanced Solid Tumors	5
Lipid-Lowering RNA Therapeutics for Atherosclerotic Cardiovascular Disease Prevention: A State−of−the−Art Review	5
Malaysian Hospital Pharmacists’ Perspectives and Their Role in Promoting Biosimilar Prescribing: A Nationwide Survey	5
Recombinant Molecules as a New Frontier in Mucositis Therapy	5
Toward Regulatory Convergence and Streamlined Biosimilar Development: Recommendations from an International Qualitative Study	5
Recent Developments in Lipid Nanoparticle-Mediated Delivery of Biotherapeutics and Gene Therapy Across the Blood–Brain Barrier	5
The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US	5
Research Advances in Stem Cell Therapy for Erectile Dysfunction	5
Biological Therapies in Chronic Obstructive Pulmonary Disease: New Directions in Personalised Respiratory Medicine	5
Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome)	5
Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings	5
Postmarketing Reports of Incomplete Dosing-Related Complications with Self-Injected PCSK9 Inhibitors: A Descriptive Study and Disproportionality Analysis	5
Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database	5
Recombinant Antibody Fragments for Immunotherapy of Parkinson’s Disease	5